Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly influence overall and disease-free survival in selected patients suffering from peritoneal surface malignancies (PSM) of various tumor entities. Because of the extent of the therapeutic approach, the associated morbidity and mortality and the multidisciplinarity need, implementation of a CRS + HIPEC program at an institution is often challenging. Cytoreductive surgery (CRS) is a complex operation in which doctors remove all visible tumors within the abdomen. Immediately following surgery, doctors deliver heated chemotherapy solution (HIPEC) directly into the abdomen to kill any remaining tumor cells.

Common Symptoms

  • Stomach cancer
  • Appendix cancer
  • Colorectal cancer
  • Malignant peritoneal mesothelioma
  • Ovarian cancer